Severi C, Tattoli I, Corleto V D, Maselli M A, Trisolini P, Delle Fave G
Department of Clinical Sciences, University La Sapienza, Rome, Italy.
Neurogastroenterol Motil. 2006 Nov;18(11):1009-18. doi: 10.1111/j.1365-2982.2006.00822.x.
Vasoactive intestinal peptide (VIP) relaxes smooth muscle by interacting with receptors coupled to cAMP- or cGMP-signalling pathways. Their relative contribution to human gastric relaxation is unknown. This study aimed at investigating, in terms of biological activity, receptor expression and related signalling pathways, the action of VIP separately on the human fundus and the antrum. VIP caused greater relaxation of smooth muscle cells (SMC) and strips of the antrum presenting on the former a higher efficacy and potency (ED(50): 0.53 +/- 0.17 nmol L(-1)) than on the fundus (ED(50): 3.4 +/- 1.4 nmol L(-1)). On both fundus and antrum strips, its effect was tetrodotoxin insentitive. Reverse transcriptase-polymerase chain reaction analysis showed the sole expression of VPAC2 and natriuretic peptide clearance receptors, with VPAC2 being more abundant in the antrum. Functional regional differences in receptor-related signalling pathways were found. Activation of the cAMP-pathway by forskolin or its inhibition by adenylate cyclase (2'5'-dideoxyadenosine) or kinase (Rp-cAMPs) inhibitors had more pronounced effects on antrum SMC. Activation of the cGMP-pathway by sodium nitroprusside or its inhibition by guanylate cyclase (LY83583) or kinase (KT5823) inhibitors had more effects on fundus SMC, on which a higher expression of endothelial nitric oxide synthase was found. In conclusion, regional differences in VIP action on human stomach are related to distinct myogenic properties of SMC of the antrum and the fundus.
血管活性肠肽(VIP)通过与偶联至cAMP或cGMP信号通路的受体相互作用来舒张平滑肌。它们对人类胃舒张的相对贡献尚不清楚。本研究旨在从生物学活性、受体表达及相关信号通路方面,探讨VIP分别对人胃底和胃窦的作用。VIP对胃窦平滑肌细胞(SMC)和肌条的舒张作用更强,其对前者的效能和效价更高(半数有效剂量[ED(50)]:0.53±0.17 nmol L(-1)),而对胃底的ED(50)为3.4±1.4 nmol L(-1)。在胃底和胃窦肌条上,其作用均不受河豚毒素影响。逆转录聚合酶链反应分析显示仅表达VPAC2和利钠肽清除受体,且VPAC2在胃窦中更为丰富。发现受体相关信号通路存在功能上的区域差异。福司可林激活cAMP通路或腺苷酸环化酶(2'5'-二脱氧腺苷)或激酶(Rp-cAMPs)抑制剂抑制该通路,对胃窦SMC的影响更为显著。硝普钠激活cGMP通路或鸟苷酸环化酶(LY83583)或激酶(KT5823)抑制剂抑制该通路,对胃底SMC的影响更大,且在胃底SMC上发现内皮型一氧化氮合酶的表达更高。总之,VIP对人胃作用的区域差异与胃窦和胃底SMC不同的肌源性特性有关。